Compound News and Research

RSS

New drug shows potential against rare type of acute leukemia

Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well.

30 Mar 2015

Stopping cellular quality-control mechanism can make chemotherapy more effective

A University of Rochester team found a way to make chemotherapy more effective, by stopping a cellular quality-control mechanism, according to a study published today in Nature Communications.

27 Mar 2015

UVA researchers develop compound that could lead to improved leukemia treatments

Researchers at the University of Virginia School of Medicine have developed a compound that delays leukemia in mice and effectively kills leukemia cells in human tissue samples, raising hopes that the drug could lead to improved treatments in people. The researchers call it an exciting "new paradigm" for treating leukemia.

26 Mar 2015

Research opens door to new prostate cancer treatment

Researchers from the Centenary Institute’s Origins of Cancer Program have discovered new links between nutrition and prostate cancer.

26 Mar 2015

AstraZeneca, HSCI collaborate to find new treatments for diabetes

AstraZeneca today announced that it has entered into a five-year research collaboration with the Harvard Stem Cell Institute to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.

26 Mar 2015

BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed two new method of treatment patent applications with the United States Patent and Trademark Office to cover methods of treating brain tumors as well as cancers expressing a mutant form of RAS protein through administration of the Company’s lead compound, Plinabulin.

26 Mar 2015

Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor.

24 Mar 2015

Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Research results published in the Journal of Neurotrauma and conducted by the Walter Reed Army Institute of Research (WRAIR) as part of a collaboration with Concert Pharmaceuticals, Inc. showed that a novel deuterium-containing sigma-1 agonist invented at Concert, called C-10068, demonstrated anti-seizure and anti-inflammatory effects in a preclinical model of traumatic brain injury (TBI).

24 Mar 2015

Vitamin D3 and metformin show promising results in preventing colorectal cancer

The concept was simple: If two compounds each individually show promise in preventing colon cancer, surely it's worth trying the two together to see if even greater impact is possible.

24 Mar 2015

Saccharin could potentially lead to development of drugs for difficult-to-treat cancers

Saccharin, the artificial sweetener that is the main ingredient in Sweet 'N Low, Sweet Twin and Necta, could do far more than just keep our waistlines trim. According to new research, this popular sugar substitute could potentially lead to the development of drugs capable of combating aggressive, difficult-to-treat cancers with fewer side effects.

23 Mar 2015

Chemical found in stinging nettles and ants could improve cancer drug

A cancer drug could be made 50 times more effective by a chemical found in stinging nettles and ants, new research finds.

20 Mar 2015

BAI researchers develop new brain image analysis method to better track amyloid changes

Researchers from Banner Alzheimer's Institute have developed a new brain image analysis method to better track the progression of beta-amyloid plaque deposition, a characteristic brain abnormality in Alzheimer's disease, according to a study published in the March issue of the Journal of Nuclear Medicine.

20 Mar 2015

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma, Inc., a privatively held biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare diseases, announced today that its lead compound tacrolimus (SPI-026) has been granted Orphan Drug Designation by the U.S. Food & Drug Administration for the treatment of pulmonary arterial hypertension (PAH).

18 Mar 2015

Researchers discover new metabolic mechanisms linked to macrophage polarization

A group of researchers from Washington University in St. Louis, Agios Pharmaceuticals and ITMO University has discovered new metabolic mechanisms that regulate macrophage polarization - the unique ability of these immune cells to change their specialization depending on the required task.

18 Mar 2015

Gentronix signs three-year technology access deal with SIMM

UK based Gentronix Limited, the specialist genetic toxicology company, today announced it has signed a three year technology access deal with one of China's most prestigious research intensive institutes, Shanghai Institute Materia Medica, Chinese Academy of Sciences.

18 Mar 2015

Compound News and Research

New drug shows potential against rare type of acute leukemia

Stopping cellular quality-control mechanism can make chemotherapy more effective

UVA researchers develop compound that could lead to improved leukemia treatments

Research opens door to new prostate cancer treatment

AstraZeneca, HSCI collaborate to find new treatments for diabetes

BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

Rigontec raises €4.8 million in second closing of Series A financing round

Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Vitamin D3 and metformin show promising results in preventing colorectal cancer

Saccharin could potentially lead to development of drugs for difficult-to-treat cancers

Chemical found in stinging nettles and ants could improve cancer drug

BAI researchers develop new brain image analysis method to better track amyloid changes

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Researchers discover new metabolic mechanisms linked to macrophage polarization

Gentronix signs three-year technology access deal with SIMM

TSRI scientists successfully test potential preventative therapy for type 1 diabetes in animal models

Hydrazine not prevalent in smokeless tobacco products

New antibody treatment blocks immune signaling protein crucial to psoriasis

Gene variant may help predict people’s response to investigational Alzheimer's therapy

TSRI chemists develop innovative method for building new drug molecules

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News